Trial
NCT05183139
A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Takeda
Collaborators
—
Condition
Multiple Myeloma
Intervention
Ixazomib
Why stopped
Business decision (no enrollment)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-03